We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Pharmacokinetic Study of CVX-096 (PF-04856883) in Healthy Volunteers

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01637285
First Posted: July 11, 2012
Last Update Posted: July 31, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Pfizer
June 26, 2012
July 11, 2012
July 31, 2015
August 2012
January 2013   (Final data collection date for primary outcome measure)
PF-04856883 Pharmacokinetics including Cmax, Tmax, AUCo-infinity, AUClast, Cl/F, Vz/F and t1/2 [ Time Frame: 4 weeks ]
Same as current
Complete list of historical versions of study NCT01637285 on ClinicalTrials.gov Archive Site
  • Number of subjects with AEs reported [ Time Frame: 4 weeks ]
  • Number of subjects with abnormal physical examination findings [ Time Frame: 4 weeks ]
  • Number of subjects with abnormal clinical laboratory results [ Time Frame: 4 weeks ]
  • Number of subjects with abnormal ECGs [ Time Frame: 4 weeks ]
  • Number of subjects with abnormal vital signs [ Time Frame: 4 weeks ]
Same as current
Not Provided
Not Provided
 
A Pharmacokinetic Study of CVX-096 (PF-04856883) in Healthy Volunteers
A Phase 1, Randomized, Open-label, Parallel-group Study To Evaluate The Pharmacokinetics Of Pf-04856883 (Cvx-096) Following Subcutaneous Administration In Healthy Volunteers
The purpose of the study is to further evaluate the PK characteristics of PF-04856883.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Healthy
  • Biological: PF-04856883
    Dose A
  • Biological: PF-04856883
    Dose B
  • Biological: PF-04856883
    Dose C
  • Biological: PF-04856883
    Dose D
  • Experimental: PF-04856883 Treatment Arm 1
    Intervention: Biological: PF-04856883
  • Experimental: PF-04856883 Treatment Arm 2
    Intervention: Biological: PF-04856883
  • Experimental: PF-04856883 Treatment Arm 3
    Intervention: Biological: PF-04856883
  • Experimental: PF-04856883 Treatment Arm 4
    Intervention: Biological: PF-04856883
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
49
January 2013
January 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Exclusion Criteria:

Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01637285
B1111005
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
July 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP